Phase II study of pemetrexed maintenance with or without bevacizumab after a first line treatment chemotherapy with bevacizumab-carboplatin-pemetrexed in patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer

Phase II study of pemetrexed maintenance with or without bevacizumab after a first line treatment chemotherapy with bevacizumab-carboplatin-pemetrexed in patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer - BPOP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010002

Enrollment

110

Registered

2013-02-08

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

2011/07/01-2014/06/01 bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced, metastatic or recurrent NSCLC PS(ECOG) 0-1 Additional eligibility criteria included Adequate function of the bone marrow, liver and kidney. All patients provided written informed consent

Exclusion criteria

Exclusion criteria: interstitial lung disease history of hemoptysis myocardial infarction,unstable angina, stroke, transient ischemic attack significant vascular disease bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation hypertension or history of hypertensive crisis or encephalopathy; known CNS disease, except brain metastases treated with radiotherapy pregnancy abdominal fistula, or gastrointestinal perforation poorly controlled active ulcer known hypersensitivity to drug

Design outcomes

Primary

Measure	Time frame
progression-free survival for 9 months	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026